4.8 Article

Rapid and simultaneous visual screening of SARS-CoV-2 and influenza virufses with customized isothermal amplification integrated lateral flow strip

Journal

BIOSENSORS & BIOELECTRONICS
Volume 197, Issue -, Pages -

Publisher

ELSEVIER ADVANCED TECHNOLOGY
DOI: 10.1016/j.bios.2021.113771

Keywords

SARS-CoV-2; Influenza virus; Recombinase polymerase amplification; Lateral flow strip; Simultaneous identification

Funding

  1. NSFC [32172295, 21804028]
  2. Ministry of Science and Technology of China [2018YFC1603606]
  3. key R&D program of Anhui [202004a07020002, 202004a07020004, 201904d07020016]
  4. Anhui Provincial NSF [1908085QC121]
  5. China Postdoctoral Science Foundation [2019M652167]
  6. Fund of State Key Lab of Chemo/Bio-sensing and Chemometrics (Hunan University)
  7. Young and Middle-aged Leading Scientists, Engineers and Innovators of the XPCC [2019CB017, CARS-48]
  8. China Agriculture Research System-48 [CARS-48]

Ask authors/readers for more resources

This work introduces a new detection technology that can simultaneously test for SARS-CoV-2 and influenza viruses, with advantages such as speed, high sensitivity, no cross-reactivity, and false positives. Its clinical application demonstrates high accuracy, and this portable device is expected to meet the global healthcare system's need for online monitoring of serious infectious diseases.
Due to the similar clinical symptoms of influenza (Flu) and coronavirus disease 2019 (COVID-19), there is a looming infection threat of concurrent Flu viruses and severe acute respiratory syndrome coronavirus 2 (SARSCoV-2). In this work, we introduce a customized isothermal amplification integrated lateral flow strip (LFS) that is capable performing duplex reverse transcription-recombinase polymerase amplification (RT-RPA) and colorimetric LFS in a sequential manner. With customized amplification primer sets targeted to SARS-CoV-2 (opening reading frame 1a/b and nucleoprotein genes) and Flu viruses (Flu A and Flu B), the platform allows the rapid and simultaneous visual screening of SARS-CoV-2 and Flu viruses (Flu A and Flu B) without cross reactivity, false positives, and false negatives. Moreover, it maximally eases the detection, reduces the detection time (1 h), and improves the assay performance to detect as low as 10 copies of the viral RNA. Its clinical application is powerfully demonstrated with 100% accuracy for evaluating 15 SARS-CoV-2-positive clinical samples, 10 Flu viruses-positive clinical samples, and 5 negative clinical samples, which were pre-confirmed by standard qRT-PCR. We envision this portable device can meet the increasing need of online monitoring the serious infectious diseases that substantially affects health care systems worldwide.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available